Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

Leukemia & lymphoma - 1 Mar 2023

Qualls David, Noy Ariela, Straus David, Matasar Matthew, Moskowitz Craig, Seshan Venkatraman, Dogan Ahmet, Salles Gilles, Younes Anas, Zelenetz Andrew D, Batlevi Connie Lee

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CREB-Binding Protein
Share to E1A-Associated p300 Protein
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Non-Hodgkin

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 36642966
DOI: 10.1080/10428194.2022.2164194
PMCID: PMC10841916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.PMID 36642966Read ↗

Targeting epigenetic regulators in the treatment of T-cell lymphoma.Semantic proximity Read ↗

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Semantic proximity Read ↗

Predicting response to epigenetic therapySemantic proximity Read ↗

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphomaSemantic proximity Read ↗

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with ImmunotherapySemantic proximity Read ↗

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitorSemantic proximity Read ↗

CREBBP alterations are associated with a poor prognosis in de novo AML.Semantic proximity Read ↗

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.Semantic proximity Read ↗

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesSemantic proximity Read ↗

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activationSemantic proximity Read ↗

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.